Discovery and assessment of water soluble coumarins as inhibitors of the coagulation contact pathway

Charlotte Bouckaert, Shu Zhu, José W.P. Govers-Riemslag, Maxime Depoorter, Scott L. Diamond, Lionel Pochet

Research output: Contribution to journalArticle

Abstract

Over the last decade, the coagulation factor XIIa (FXIIa) has seen renewed interest as a therapeutic target. Indeed, its inhibition could offer a protection against thrombosis without increasing the risk of bleeding. Moreover, it could answer the need for a safe prevention of blood-contacting medical devices-related thrombosis. Among the FXII and FXIIa inhibitors already described in literature, organic small-molecular-weight inhibitors are rather left behind. In this study, we were focused on the discovery and assessment of water soluble small molecules. First, a search within our library of compounds flagged two promising hits. Indeed, enzymes and plasma assays suggested they have a greater activity on the contact factors (FXIa, plasma kallikrein and FXIIa) than on the TF pathway. Then, simple pharmacomodulations were undertaken with the aim to design more selective FXIIa inhibitors. This afforded compounds having different degrees of selectivity. All compounds were finally screened in whole blood using an 8-channel microfluidic model and thromboelastometry measurements. Interestingly, all molecules interfered with the thrombus formation and one of them could be considered as a small organic contact inhibitor.

Original languageEnglish
Pages (from-to)126-133
Number of pages8
JournalThrombosis Research
Volume157
DOIs
Publication statusPublished - 1 Sep 2017

Fingerprint

Coumarins
Factor XIIa
Thrombosis
Water
Plasma Kallikrein
Thrombelastography
Microfluidics
Enzyme Assays
Molecular Weight
Hemorrhage
Equipment and Supplies
factor XIIa inhibitor
Therapeutics

Keywords

  • Contact system
  • Coumarin
  • Factor XII
  • FXII
  • FXIIa
  • Inhibitor

Cite this

Bouckaert, Charlotte ; Zhu, Shu ; Govers-Riemslag, José W.P. ; Depoorter, Maxime ; Diamond, Scott L. ; Pochet, Lionel. / Discovery and assessment of water soluble coumarins as inhibitors of the coagulation contact pathway. In: Thrombosis Research. 2017 ; Vol. 157. pp. 126-133.
@article{3cfed8b8c90940969a6bb81769e5c005,
title = "Discovery and assessment of water soluble coumarins as inhibitors of the coagulation contact pathway",
abstract = "Over the last decade, the coagulation factor XIIa (FXIIa) has seen renewed interest as a therapeutic target. Indeed, its inhibition could offer a protection against thrombosis without increasing the risk of bleeding. Moreover, it could answer the need for a safe prevention of blood-contacting medical devices-related thrombosis. Among the FXII and FXIIa inhibitors already described in literature, organic small-molecular-weight inhibitors are rather left behind. In this study, we were focused on the discovery and assessment of water soluble small molecules. First, a search within our library of compounds flagged two promising hits. Indeed, enzymes and plasma assays suggested they have a greater activity on the contact factors (FXIa, plasma kallikrein and FXIIa) than on the TF pathway. Then, simple pharmacomodulations were undertaken with the aim to design more selective FXIIa inhibitors. This afforded compounds having different degrees of selectivity. All compounds were finally screened in whole blood using an 8-channel microfluidic model and thromboelastometry measurements. Interestingly, all molecules interfered with the thrombus formation and one of them could be considered as a small organic contact inhibitor.",
keywords = "Contact system, Coumarin, Factor XII, FXII, FXIIa, Inhibitor",
author = "Charlotte Bouckaert and Shu Zhu and Govers-Riemslag, {Jos{\'e} W.P.} and Maxime Depoorter and Diamond, {Scott L.} and Lionel Pochet",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.thromres.2017.07.015",
language = "English",
volume = "157",
pages = "126--133",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier",

}

Discovery and assessment of water soluble coumarins as inhibitors of the coagulation contact pathway. / Bouckaert, Charlotte; Zhu, Shu; Govers-Riemslag, José W.P.; Depoorter, Maxime; Diamond, Scott L.; Pochet, Lionel.

In: Thrombosis Research, Vol. 157, 01.09.2017, p. 126-133.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Discovery and assessment of water soluble coumarins as inhibitors of the coagulation contact pathway

AU - Bouckaert, Charlotte

AU - Zhu, Shu

AU - Govers-Riemslag, José W.P.

AU - Depoorter, Maxime

AU - Diamond, Scott L.

AU - Pochet, Lionel

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Over the last decade, the coagulation factor XIIa (FXIIa) has seen renewed interest as a therapeutic target. Indeed, its inhibition could offer a protection against thrombosis without increasing the risk of bleeding. Moreover, it could answer the need for a safe prevention of blood-contacting medical devices-related thrombosis. Among the FXII and FXIIa inhibitors already described in literature, organic small-molecular-weight inhibitors are rather left behind. In this study, we were focused on the discovery and assessment of water soluble small molecules. First, a search within our library of compounds flagged two promising hits. Indeed, enzymes and plasma assays suggested they have a greater activity on the contact factors (FXIa, plasma kallikrein and FXIIa) than on the TF pathway. Then, simple pharmacomodulations were undertaken with the aim to design more selective FXIIa inhibitors. This afforded compounds having different degrees of selectivity. All compounds were finally screened in whole blood using an 8-channel microfluidic model and thromboelastometry measurements. Interestingly, all molecules interfered with the thrombus formation and one of them could be considered as a small organic contact inhibitor.

AB - Over the last decade, the coagulation factor XIIa (FXIIa) has seen renewed interest as a therapeutic target. Indeed, its inhibition could offer a protection against thrombosis without increasing the risk of bleeding. Moreover, it could answer the need for a safe prevention of blood-contacting medical devices-related thrombosis. Among the FXII and FXIIa inhibitors already described in literature, organic small-molecular-weight inhibitors are rather left behind. In this study, we were focused on the discovery and assessment of water soluble small molecules. First, a search within our library of compounds flagged two promising hits. Indeed, enzymes and plasma assays suggested they have a greater activity on the contact factors (FXIa, plasma kallikrein and FXIIa) than on the TF pathway. Then, simple pharmacomodulations were undertaken with the aim to design more selective FXIIa inhibitors. This afforded compounds having different degrees of selectivity. All compounds were finally screened in whole blood using an 8-channel microfluidic model and thromboelastometry measurements. Interestingly, all molecules interfered with the thrombus formation and one of them could be considered as a small organic contact inhibitor.

KW - Contact system

KW - Coumarin

KW - Factor XII

KW - FXII

KW - FXIIa

KW - Inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85025065861&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2017.07.015

DO - 10.1016/j.thromres.2017.07.015

M3 - Article

VL - 157

SP - 126

EP - 133

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

ER -